MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Neither of the vaccines, Pfizer Abrysvo made by Pfizer ... have had no serious side effects, the CDC says. FDA approves first ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where it won’t have to face ...
Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback